Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (presently amended) ~~The present invention relates to a variety of compounds which are useful according to the present invention. These compounds are~~ A method of treating glaucoma or lowering or controlling intraocular pressure in a subject comprising administering to the subject a compound represented by the following Formula A:



A

wherein **R, R^1** and **R^2** are independently chosen from hydrogen, C_{1-4}alkyl;

R^3 is selected from hydrogen, C_{1-4}alkyl, or R^2 and R^3 can complete a pyrrolidine or piperidine ring, which can be substituted with C_{1-4}alkyl;

R^4 is hydrogen, halogen, C_{1-4}alkyl;

R^5 and **R^6** are independently chosen from hydrogen, halogen, C_{1-6}alkyl, C_{1-6}alkylthio, C_{1-6}alkylsulfonyl, C_{1-6}alkylsulfoxide, nitrile, C_{1-6}alkyl substituted with halogen;

R^7 is chosen from

$C{=}OR^9$;

$S(O)_mR^{10}$;

NR^1-(C=O)-R^{11};

C_{1-6}alkyl substituted with hydroxyl, C_{1-6}alkoxy, $OC(=O)C_{1-8}$, CO_2H,

CO_2C_{1-6}alkyl, $C(=O)NR^{12}R^{13}$, $S(O)_mNR^{12}R^{13}$, $NR^{14}R^{15}$, phenyl or a saturated or unsaturated 5 or 6-membered heterocyclic ring which can contain 1-4 heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C_{1-6}alkyl, C_{1-6}alkoxy, halogen, haloC_{1-4}alkyl, phenyl or pyridinyl; or **R^7** can be chosen from a heterocyclic ring selected from oxazol-2-yl; 4,5-dihydro-oxazol-2-yl~~,~~; ~~or~~ benzoxazol-2-yl; 5,6-dihydro-[1,3]oxazin-2-yl; thiazol-2-yl; 4,5-dihydro- thiazol-2-yl; ~~or~~ benzothiazol-2-yl; imidazol-2-yl; imidazolidin-2-yl; [1,2,4]oxadiazol-5-yl~~,~~; [1,2,4]oxadiazol-3-yl; [1,2,4]thiadiazol-5-yl; or [1,2,4]thiadiazol-3-yl, each of which can be unsubstituted or substituted with C_{1-6}alkyl, C_{1-6}alkoxy, phenyl, pyridinyl, or

C_{1-6}alkyl substituted with phenyl or pyridinyl;

but **R^7** cannot be hydrogen, lower alkyl, hydroxyl, lower alkoxy, amino, mono- or di-loweralkyl amino, lower alkanoylamino, or halogen;

R^8 is selected from C_{1-6}alkyl, phenyl which can be substituted with C_{1-6}alkyl, C_{1-6}alkoxy, $NR^1(C=O)C_{1-6}$alkyl, or halogen;

R^9 is chosen from hydroxyl; C_{1-6}alkoxy; C_{1-6}alkoxy substituted with phenyl or pyridinyl which can be substituted with C_{1-4}alkoxy or halogen; $NR^{16}R^{17}$; C_{1-6}alkyl; or C_{1-6}alkyl substituted with hydroxyl, C_{1-6}alkoxy, $NR^{12}R^{13}$, CO_2H, CO_2C_{1-6}alkyl, $S(O)_mNR^{12}R^{13}$, halogen, or phenyl or a heterocyclic ring selected from pyrrolidinyl, imidazoyl, morpholinyl, oxazolyl, isoxazolyl, thiazolyl, or tetrazolyl, or pyridinyl which can be unsubstituted or substituted with C_{1-6}alkyl, C_{1-6}alkoxy, halogen, haloC_{1-4}alkyl;

R^{10} is chosen from $NR^{12}R^{13}$; C_{1-6}alkyl; CH_2phenyl or CH_2pyridinyl which can be substituted with C_{1-6}alkyl, C_{1-6}alkoxy, halogen, or haloC_{1-4}alkyl; or C_{2-6}alkyl substituted with hydroxyl, C_{1-6}alkoxy, $NR^{12}R^{13}$, CO_2H, CO_2C_{1-6}alkyl, phenyl, pyridinyl or imidazolyl which can be substituted with C_{1-6}alkyl, C_{1-6}alkoxy, halogen, haloC_{1-4}alkyl;

R^{11} is NH_2; NR^1R^2; C_{1-6}alkyl substituted with hydroxyl, C_{1-6}alkoxy, CO_2H, CO_2C_{1-6}-alkyl, phenyl or a saturated or unsaturated 5 or 6-membered heterocyclic ring which can contain 1-4 heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C_{1-6}alkyl, C_{1-6}alkoxy, halogen, haloC_{1-4}alkyl;

R^{12} and **R^{13}** are independently selected from hydrogen; C_{1-6}alkyl; CH_2Z, where Z is selected from phenyl, pyridinyl, furanyl, thiophenyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and which can be substituted with C_{1-6}alkyl, C_{1-6}alkoxy, halogen, or haloC_{1-4}alkyl; C_{2-6}alkyl substituted with hydroxyl, C_{1-6}alkoxy, CO_2H, CO_2C_{1-6}alkyl, NR^1COC_{1-6}alkyl, or halogen; or R^{12}, R^{13}, and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C_{1-4}alkyl or C_{1-4}alkyl substituted with hydroxy, C_{1-4}alkoxy or halogen;

R^{14} and **R^{15}** are independently selected from hydrogen, C_{1-6}alkyl, hydroxyl, C_{1-6}alkoxy, (C=O)-R^{11}, $S(O)_mR^8$, phenyl or pyridinyl which can be substituted with C_{1-6}alkyl, C_{1-6}alkoxy, halogen, or haloC_{1-4}alkyl; or R^{14} , R^{15} and the nitrogen atom to which they are attached can form a heterocyclic ring selected from pyrrolidine, piperazine, or piperidine, which can be substituted with C_{1-6}alkyl, phenyl, or pyridinyl;

R^{16} and **R^{17}** are independently selected from hydrogen; C_{1-6}alkyl; hydroxyl; C_{1-6}alkoxy; CH_2Z, where Z is selected from phenyl, pyridinyl, furanyl, thiophenyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and which can be substituted with C_{1-6}alkyl, C_{1-6}alkoxy, halogen, or haloC_{1-4}alkyl; C_{2-6}alkyl substituted with hydroxyl, C_{1-6}alkoxy, halogen, $NR^1(C=O)C_{1-6}$alkyl, or a phenyl or a heterocyclic ring selected from ~~a pyrrole, such as~~ pyrrolidin-2-yl~~,~~; ~~an imidazole such as~~ imidazo-2-yl~~,~~; ~~or~~ imidazo-4-yl~~,~~; ~~a morpholine such as~~ morpholin-3-yl~~,~~; ~~a piperidine such as~~ piperidin-4-yl~~,~~; oxazolyl~~,~~; isoxazolyl~~,~~; thiazolyl~~,~~; tetrazolyl~~,~~; pyridinyl~~,~~; each of which can be unsubstituted or substituted with C_{1-6}alkyl, C_{1-6}alkoxy, halogen, haloC_{1-4}alkyl, phenylC_{1-4}alkyl, oxo

(=O); or R^{16}, R^{17}, and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C_{1-4}alkyl or C_{1-4}alkyl substituted with hydroxy, oxo (=O), C_{1-4}alkoxy, or phenyl;

m is 0 – 2;

A is N or CH; and

X and **Y** are either N or C, wherein X and Y cannot be the same; and the dashed bonds denote a suitably appointed single and double bond.

2. (presently amended) The method of claim 1, wherein for the compound of Formula A:

R, R^1 and **R^2** are independently chosen from hydrogen, C_{1-4}alkyl;

R^3 is selected from hydrogen, C_{1-4}alkyl, or R^2 and R^3 can complete a pyrrolidine or piperidine ring, which can be substituted with C_{1-4}alkyl;

R^4 is hydrogen, C_{1-4}alkyl;

R^5 and **R^6** are independently chosen from hydrogen, halogen, C_{1-6}alkyl, C_{1-6}alkylthio, C_{1-6}alkylsulfonyl, C_{1-6}alkylsulfoxide, nitrile, C_{1-6}alkyl substituted with halogen;

R^7 is chosen from

$C{=}OR^9$;

C_{1-6}alkyl substituted with hydroxyl, C_{1-6}alkoxy, $OC(=O)C_{1-8}$, CO_2H, CO_2C_{1-6}alkyl, $C(=O)NR^{12}R^{13}$, $S(O)_mNR^{12}R^{13}$, $NR^{14}R^{15}$, phenyl or a saturated or unsaturated 5 or 6-membered heterocyclic ring which can contain 1-4 heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C_{1-6}alkyl, C_{1-6}alkoxy, halogen, haloC_{1-4}alkyl, phenyl or pyridinyl; or

R^7 can be chosen from a heterocyclic ring selected from oxazol-2-yl; 4,5-dihydro-oxazol-2-yl; benzoxazol-2-yl; 5,6-dihydro-[1,3]oxazin-2-yl; thiazol-2-yl; 4,5-dihydro-thiazol-2-yl; benzothiazol-2-yl; imidazol-2-yl; imidazolidin-2-yl;

[1,2,4]oxadiazol-5-yl; [1,2,4]oxadiazol-3-yl; [1,2,4]thiadiazol-5-yl; or [1,2,4]thiadiazol-3-yl, each of which can be unsubstituted or substituted with C_{1-6}alkyl, C_{1-6}alkoxy, phenyl, pyridinyl, or C_{1-6}alkyl substituted with phenyl or pyridinyl;

but **R^7** cannot be hydrogen, lower alkyl, hydroxyl, lower alkoxy, amino, mono- or di-loweralkyl amino, lower alkanoylamino, or halogen;

R^8 is selected from C_{1-6}alkyl, phenyl which can be substituted with C_{1-6}alkyl, C_{1-6}alkoxy, $NR^1(C=O)C_{1-6}$alkyl, or halogen;

R^9 is chosen from hydroxyl; C_{1-6}alkoxy; C_{1-6}alkoxy substituted with phenyl or pyridinyl which can be substituted with C_{1-4}alkoxy or halogen; $NR^{16}R^{17}$; C_{1-6}alkyl; or C_{1-6}alkyl substituted with hydroxyl, C_{1-6}alkoxy, $NR^{12}R^{13}$, CO_2H, CO_2C_{1-6}alkyl, $S(O)_mNR^{12}R^{13}$, halogen, or phenyl or a heterocyclic ring selected from pyrrolidinyl, imidazoyl, morpholinyl, oxazolyl, isoxazolyl, thiazolyl, or tetrazolyl, or pyridinyl which can be unsubstituted or substituted with C_{1-6}alkyl, C_{1-6}alkoxy, halogen, haloC_{1-4}alkyl;

R^{11} is NH_2; NR^1R^2; C_{1-6}alkyl substituted with hydroxyl, C_{1-6}alkoxy, CO_2H, CO_2C_{1-6}-alkyl, phenyl or a saturated or unsaturated 5 or 6-membered heterocyclic ring which can contain 1-4 heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C_{1-6}alkyl, C_{1-6}alkoxy, halogen, haloC_{1-4}alkyl;

R^{12} and **R^{13}** are independently selected from hydrogen; C_{1-6}alkyl; CH_2Z, where Z is selected from phenyl, pyridinyl, furanyl, thiophenyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and which can be substituted with C_{1-6}alkyl, C_{1-6}alkoxy, halogen, or haloC_{1-4}alkyl; C_{2-6}alkyl substituted with hydroxyl, C_{1-6}alkoxy, CO_2H, CO_2C_{1-6}alkyl, NR^1COC_{1-6}alkyl, or halogen; or R^{12}, R^{13}, and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C_{1-4}alkyl or C_{1-4}alkyl substituted with hydroxy, C_{1-4}alkoxy or halogen;

R^{14} and **R^{15}** are independently selected from hydrogen, C_{1-6}alkyl, hydroxyl, C_{1-6}alkoxy, (C=O)-R^{11}, $S(O)_mR^8$, phenyl or pyridinyl which can be substituted with C_{1-6}alkyl, C_{1-6}alkoxy, halogen, or haloC_{1-4}alkyl; or R^{14} , R^{15} and the nitrogen atom to which they are attached can form a heterocyclic ring selected from pyrrolidine, piperazine, or piperidine, which can be substituted with C_{1-6}alkyl, phenyl, or pyridinyl;

R^{16} and **R^{17}** are independently selected from hydrogen; C_{1-6}alkyl; hydroxyl; C_{1-6}alkoxy; CH_2Z, where Z is selected from phenyl, pyridinyl, furanyl, thiophenyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and which can be substituted with C_{1-6}alkyl, C_{1-6}alkoxy, halogen, or haloC_{1-4}alkyl; C_{2-6}alkyl substituted with hydroxyl, C_{1-6}alkoxy, halogen, $NR^1(C=O)C_{1-6}$alkyl, or a phenyl or a heterocyclic ring selected from ~~a pyrrole, such as~~ pyrrolidin-2-yl~~,~~; ~~an imidazole such as~~ imidazo-2-yl~~,~~; ~~or~~ imidazo-4-yl~~,~~; ~~a morpholine such as~~ morpholin-3-yl~~,~~; ~~a piperidine such as~~ piperidin-4-yl~~,~~; oxazolyl~~,~~; isoxazolyl~~,~~; thiazolyl~~,~~; tetrazolyl~~,~~; pyridinyl~~,~~; each of which can be unsubstituted or substituted with C_{1-6}alkyl, C_{1-6}alkoxy, halogen, haloC_{1-4}alkyl, phenylC_{1-4}alkyl, oxo (=O); or R^{16}, R^{17}, and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C_{1-4}alkyl or C_{1-4}alkyl substituted with hydroxy, oxo (=O), C_{1-4}alkoxy, or phenyl;

m is 0 – 2;

A is N; and

X and **Y** are either N or C, wherein X and Y cannot be the same; and the dashed bonds denote a suitably appointed single and double bond.

3. (original) The method of claim 2, wherein the compound of Formula A is:

1-((S)-2-aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid amide;

1-((S)-2-aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid methyl amide fumarate;

1-((*S*)-2-aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid (1-hydroxy-cyclopropylmethyl)-amide; or

1-((*S*)-2-aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid (3-hydroxy-2,2-dimethyl-propyl)-amide.

4. (original) The method of claim 3, wherein the compound of Formula A is 1-((*S*)-2-aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid (3-hydroxy-2,2-dimethyl-propyl)-amide.

5 – 9. (Cancelled).